VR Logo

Dermata Therapeutics Inc. (DRMA) download report


Healthcare | Biotechnology & Pharma Research

Dermata Therapeutics Inc. (DRMA) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions.

IPO Date: 13-Aug-2021

Founder, Pres, CEO & Chairman: Mr. Gerald T. Proehl

Co-Founder & Lead Independent Director: Mr. David F. Hale

Listing: NASDAQ: DRMA

Country: United States

Headquarters: San Diego, CA

Website: https://www.dermatarx.com

Key Facts

Market cap: $4.43 Mln

Revenue (TTM): $0.00 Mln

Earnings (TTM): $-10.95 Mln

Cash: $8.19 Mln

Total Debt: $0.00 Mln

Insider's Holding: 42.91%

Liquidity: Low

52 Week range: $0.44 - 50.00

Shares outstanding: 9,227,210

Stock Performance

Time Period Dermata Therapeutics (DRMA) S&P BSE Sensex* S&P Small-Cap 600*
YTD-72.41-8.43-17.79
1 month-36.00-1.67-2.72
3 months-59.32-7.00-12.17
1 Year-99.040.79-15.82
3 Years-78.7510.457.14
5 Years-60.5111.376.20
10 Years--12.1810.33
As on 24-Jun-2022 *As on 27-Jun-2022
Year Dermata Therapeutics (DRMA) S&P Small-Cap 600 S&P BSE Sensex
2021-96.5225.2721.99
20200.009.5715.75
20190.0020.8614.38
20180.00-9.705.87
20170.0011.7327.91
2016-60.0024.741.95